

Feedback form

Please provide your contact details below.

Name:	
If this feedback is on behalf of an organisation, please name the organisation:	
Please provide a brief description of the organisation if applicable:	
Address/email:	
Interest in this topic (e.g. user of fertility services, health professional, researcher, member of public):	Member of public

Please refer to page v for information about:

- Publication of feedback on ACART's website
- Official Information Act requests – possible release of your feedback
- Official Information Act requests – possible release of your name and contact details

We will acknowledge all feedback.

- ☐ I **request** that my feedback be withheld in full or part from publication on ACART's website. (If you wish a part to be withheld, please clearly indicate which part.)
- ☐ I **do not** give permission for my name to be published on ACART's website.
- ☒ I **do not** give permission for my contact details to be published on ACART's website.

If you consider that your feedback, or your name and contact details (if you are submitting on behalf of an organisation), should be withheld under the Act, please state the reasons here:

Questions for response

Question 1

My apologies for my writing - I have 'essential tremor'!

Refer to sections 3 and 4.

- (a) Do you agree with ACART's assessment of the known risks and benefits to health associated with the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

The cryopreservation procedure does not, seemingly, harm the tissue to preserved. There seems to be no harmful effects on either the mother or the child as a result of using cryopreserved ovarian tissue.

- (b) Are there any risks and/or benefits associated with the use of cryopreserved ovarian tissue to restore ovarian function that ACART has not identified or assessed?

Yes ☐ No ☒

If yes, please list below.

Not that I am aware of.

Question 2

Refer to section 4.

- (a) Do you agree with ACART's conclusion that the risks associated with the use of cryopreserved ovarian tissue to restore ovarian function falls within a level that is acceptable in New Zealand?

Yes ☒ No ☐

Please give reasons for your views.

The likely benefits of the use of cryopreserved tissue greatly outweigh the ~~small~~ small risks.

- (b) Please note any other comments below.

Question 3

Refer to section 4.

- (a) Has ACART identified all the relevant areas to monitor the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

Continued monitoring of international developments is necessary, because [it is] because there is some uncertainty about eventual outcomes.

- (b) Are there any other areas ACART should monitor?

Yes ☐ No ☐

Please give reasons for your views.

Question 4

Refer to section 5.

- (a) Has ACART identified all the ethical issues relevant to the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

I think so. However your ~~recommendation~~ recommendation that the use of ovarian tissue should be limited to the woman from whom it was excised is important.

- (b) Do you agree with ACART's ethical analysis that there are no significant ethical issues associated with the use of cryopreserved ovarian tissue to restore ovarian function?

Yes ☒ No ☐

Please give reasons for your views.

Question 5

Refer to section 6.

- (a) Do you agree that the use of cryopreserved ovarian tissue to restore ovarian function should become an established procedure?

Yes ☒ No ☐

Please give reasons for your views.

The proposed advice to the Minister of Health seems well argued.

- (b) Please note any other comments below.

Question 6

Refer to section 6.

Do you agree with ACART's position that the scope for the use of cryopreserved ovarian tissue to restore ovarian function be limited to the woman from whom the tissue was excised, for her own treatment?

Yes ☒ No ☐

Please give reasons for your views.

Potential benefits to be gained are outweighed by the uncertainties & potential risks to the recipient. (see p2)

Question 7

Refer to section 6.

Do you have any further comments to share with ACART?

No

